ENGENE HOLDINGS INC.
ENGN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ENGN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ENGN
Engene Holdings Inc. is a clinical-stage biotechnology company focused on developing detalimogene voraplasmid, a gene therapy for non-muscle invasive bladder cancer (NMIBC), with no approved products and no revenue to date.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Apr 30, 2026.
Tracking 2 pipeline candidates for ENGENE HOLDINGS INC..
Engene Holdings Inc. is a clinical-stage biotechnology company focused on developing detalimogene voraplasmid, a gene therapy for non-muscle invasive bladder cancer (NMIBC), with no approved products and no revenue to date.
- Engene Holdings is a clinical-stage biotech developing detalimogene voraplasmid (detalimogene) for NMIBC, with no approved products or product revenue [sec_mda · as of 2026-06-15].
- As of April 30, 2026, the company reported cash & equivalents of $29.8M, net loss of -$30.2M for the three months ended April 30, 2026, shareholders' equity of $167.7M, and total debt of $25.1M [sec].
- In June 2026, the company implemented a strategic restructuring, reducing its workforce by approximately 50% to preserve cash while awaiting FDA discussions and LEGEND trial data [sec_mda · as of 2026-06-15].
- The company has never been profitable and expects operating losses to continue as it advances detalimogene through clinical development [sec_mda · as of 2026-06-15].
- Key near-term milestones include 12-month complete response data from the LEGEND pivotal cohort, FDA engagement, and potential BLA submission in the second half of 2026 [sec_mda · as of 2026-06-15].
What works
- Detalimogene is in a Phase 1/2 LEGEND trial with a pivotal cohort targeting BCG-unresponsive NMIBC, a high unmet medical need [sec_mda · as of 2026-06-15].
- The company has retained personnel and resources to meet key strategic goals, including completing the LEGEND Cohort 1 and planning for BLA initiation [sec · filed 2026-06-15].
- Engene has a history of securing financing through public and private offerings, debt, and warrants, indicating some capital access capability [sec_mda · as of 2026-06-15].
What to weigh
- The company has no approved products and has never generated product revenue; its future revenue depends on successful clinical development and regulatory approval [sec_mda · as of 2026-06-15].
- Cash and equivalents of $29.8M as of April 30, 2026, are limited relative to ongoing losses (net loss of $30.2M in the most recent quarter), raising the need for additional funding [sec] [sec_mda · as of 2026-06-15].
- The June 2026 workforce reduction of ~50% and halting of additional LEGEND cohorts signal significant cash conservation pressures and strategic uncertainty [sec_mda · as of 2026-06-15].
- Accumulated deficit was $401.8M as of January 31, 2026, reflecting years of losses with no near-term revenue expected [sec_mda · as of 2026-03-09].
From the filings
Quoted directly from source documents.
The company has no approved products and no product revenue.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · June 15, 2026
Workforce reduction of approximately 50% in June 2026 to preserve cash.
“we announced the implementation of a plan to reduce our workforce by approximately 50% to streamline operations and preserve cash.”
SEC MD&A · June 15, 2026
Net loss of $30.2 million for the three months ended April 30, 2026.
“Our net loss was $30.2 million and $60.0 million for the three and six months ended April 30, 2026”
SEC MD&A · June 15, 2026
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — With $29.8M cash and a quarterly net loss of $30.2M, the company may need additional funding within months [sec] [sec_mda · as of 2026-06-15].
- Regulatory and clinical risk — Detalimogene is in Phase 1/2; failure to meet endpoints or obtain FDA approval would prevent commercialization [sec_mda · as of 2026-06-15].
- Dependence on single product — The company's pipeline is concentrated on detalimogene; any setback would materially impact the business [sec_mda · as of 2026-06-15].
- Restructuring execution risk — The 50% workforce reduction may impair operational capacity and delay milestones [sec_mda · as of 2026-06-15].
What to watch
- 12-month complete response data from the LEGEND pivotal cohort [sec_mda · as of 2026-06-15].
- FDA engagement and potential BLA submission in the second half of 2026 [sec_mda · as of 2026-06-15].
- Ability to secure additional financing given reduced cash position [sec] [sec_mda · as of 2026-06-15].
- Enrollment and data from the detalimogene plus surfactant cohort [sec · filed 2026-06-15].
Sources: SEC filings · SEC MD&A · Generated August 12, 2026 · How we verify sources →
Run ENGENE HOLDINGS INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ENGENE HOLDINGS INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
24.6 months
D/E 0.21 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$2.3M
| Holder | Shares | Value |
|---|---|---|
| marshall wace, llp | 343,928 | $2.3M |
| sbi securities co., ltd. | 28 | $191 |
Short Interest
as of Apr 20, 2026- % of float
- 2.2%
- Days to cover
- 2.0
- Shares short
- 1,145,907
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ENGN short interestGovernance
Frequently asked questions
What is the AI investment thesis for ENGENE HOLDINGS INC.?
Engene Holdings Inc. is a clinical-stage biotechnology company focused on developing detalimogene voraplasmid, a gene therapy for non-muscle invasive bladder cancer (NMIBC), with no approved products and no revenue to date.
What is ENGENE HOLDINGS INC.'s lead drug candidate?
ENGENE HOLDINGS INC.'s most advanced tracked candidate is detalimogene (Phase 2) for high-risk BCG-unresponsive NMIBC with CIS.
Who is the CEO of ENGENE HOLDINGS INC.?
Mr. Ronald H. W. Cooper is the chief executive officer of ENGENE HOLDINGS INC. (ENGN).
Where is ENGENE HOLDINGS INC. headquartered?
ENGENE HOLDINGS INC. (ENGN) is headquartered in Montreal, QC, Canada.
What therapeutic areas does ENGENE HOLDINGS INC. focus on?
ENGENE HOLDINGS INC. develops therapies across Rare Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.